Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.

Neurological research - 1 Oct 2013

Vlachostergios Panagiotis J, Hatzidaki Eleana, Papandreou Christos N

Abstract excerpt

The DNA repair enzyme O6-methylguanine methyltransferase (MGMT) is a major determinant of glioma resistance to alkylating agents. Several strategies have been used to induce sensitization to alkylator-based treatments, including the direct MGMT inhibitor O6-benzylguanine (BG). However, replenishment of MGMT is often observed after the withdrawal of combined schedules of temozolomide (TMZ) and BG, thus preventing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Drug Synergism

Share to Guanine

Share to NF-kappa B

Share to Temozolomide

Source

Identifiers

PMID: 23561593
DOI: 10.1179/1743132813Y.0000000191

Genes

MGMT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.PMID 23561593Read ↗

Correlation of O<sup>6</sup>-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT ActivitySemantic proximity Read ↗

A combination of IFN-β and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulationSemantic proximity Read ↗

O<sup>6</sup>‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cellsSemantic proximity Read ↗

Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomideSemantic proximity Read ↗

Temozolomide: Mechanisms of Action, Repair and ResistanceSemantic proximity Read ↗

Multifaceted resistance of gliomas to temozolomide.Semantic proximity Read ↗

Mechanisms of Chemoresistance to Alkylating Agents in Malignant GliomaSemantic proximity Read ↗

MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.Semantic proximity Read ↗

Clinical Relevance of <i>MGMT</i> in the Treatment of CancerSemantic proximity Read ↗

Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.Semantic proximity Read ↗

Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomideSemantic proximity Read ↗

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 ExpressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.